Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Can Aydogdu

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Cancer Immunology, Immunotherapy : CII|July 12, 2026
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)Stefanie Zschäbitz, Irfan Bhatti, Jozefina Casuscelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Cancer Immunology, Immunotherapy : CII|July 12, 2026
Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)Stefanie Zschäbitz, Irfan Bhatti, Jozefina Casuscelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Pageof 3